Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Vertex Inc. (NASDAQ:VERX) is one of the best beaten down stocks to invest in according to analysts. On December 5, Vertex Inc ...

Vertex’s new diabetes cell therapy has brought many surprises: first, the rush of excitement that followed new data from a single patient last year. And now, an FDA clinical hold on a phase 1/2 trial.

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta thalassemia, “there has never been a more exciting time to be at Vertex,” ...

In the world of wristwatches, few designs carry the weight of history like the British field watch from World War II. These ...

UTime (WTO) announced its Hong Kong subsidiary, UTime Technology, has officially signed a smart health device procurement ...